Finox Biotech Australia

Finox Biotech is a biopharmaceutical company specializing in the development and commercialization of fertility treatments. The company's flagship product, BEMFOLA, is a recombinant human follicle-stimulating hormone (r-hFSH) used for the treatment of infertility. BEMFOLA was the first biosimilar r-hFSH to receive marketing authorization in the European Union and Australia, offering a cost-effective alternative to reference products. In 2016, Finox Biotech was acquired by Gedeon Richter, a major European pharmaceutical company, to strengthen its global women's healthcare portfolio. The Australian subsidiary manages the commercial presence and distribution of these fertility products within the region.